A Preclinical Candidate Targeting Mycobacterium tuberculosis KasA

Area of Science:

• Medicinal Chemistry
• Microbiology
• Drug Discovery

Background:

• Existing Mycobacterium tuberculosis KasA inhibitors have limitations in potency and pharmacokinetics.
• There is a need for improved therapeutic agents against tuberculosis.

Purpose of the Study:

• To optimize the existing KasA inhibitor DG167 using a structure-based approach.
• To develop a potent and pharmacokinetically improved inhibitor for tuberculosis treatment.

Main Methods:

• Structure-based drug design was employed to optimize DG167.
• Biochemical, genetic, and X-ray crystallography studies were conducted.
• In vivo efficacy was evaluated in acute and chronic mouse models of tuberculosis.

Main Results:

• The optimized compound, indazole JSF-3285, exhibited a 30-fold increase in mouse plasma exposure.
• JSF-3285 was confirmed to target KasA through multiple studies.
• Significant reductions in bacterial load were observed in mouse models at low oral doses (5 mg/kg daily).
• JSF-3285 enhanced the efficacy of first-line tuberculosis drugs like isoniazid and rifampicin.

Conclusions:

• JSF-3285 is a potent KasA inhibitor with favorable pharmacokinetic properties.
• The compound demonstrates significant preclinical efficacy in both acute and chronic tuberculosis models.
• JSF-3285 represents a promising preclinical candidate for tuberculosis therapy, potentially improving upon current treatment regimens.